Author:
Aapro Matti,Krendyukov Andriy,Schiestl Martin,Gascón Pere
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,General Medicine,Biotechnology
Reference43 articles.
1. Aapro M. Biosimilars in oncology: current and future perspectives. GaBI J. 2013;2:91–3.
2. Bennett CL, Chen B, Hermanson T, Wyatt MD, Schulz RM, Georgantopoulos P, Kessler S, Raisch DW, Qureshi ZP, et al. Regulatory and clinical considerations for biosimilar oncology drugs. Lancet Oncol. 2014;15:e594–605.
3. Tabernero J, Vyas M, Giuliani R, Arnold D, Cardoso F, Casali PG, Cervantes A, Eggermont AM, Eniu A, et al. Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers. ESMO Open. 2016;1:e000142.
4. European Medicines Agency (EMA). Guideline on similar biological medicinal products. European Medicines Agency. 2005.
www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003517.pdf
. Accessed 15 Jun 2017.
5. European Medicines Agency (EMA). Guideline on non-clinical and clinical development of similar biological medicinal products containing recombinant erythropoietins (Revision). European Medicines Agency. 2010.
www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/04/WC500089474.pdf
. Accessed 15 Jun 2017.
Cited by
18 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献